Clinical trial NCT05114447 - References

Asthma — Severe/Uncontrolled Asthma From General Population to Clinical Setting: Update and Follow-up of the RItA Registry

Citation(s)

•   Adachi M, Kozawa M, Yoshisue H, Lee Milligan K, Nagasaki M, Sasajima T, Miyamoto T, Ohta K
  Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan. Respir Med. 2018 Aug;141:56-63. doi: 10.1016/j.rmed.2018.06.021. Epub 2018 Jun 28.
•   Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, Jajour NN, Mauad T, Sorkness RL, Teague WG
  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343-73. doi: 10.1183/09031936.00202013. Epub 2013 Dec 12. Erratum in: Eur Respir J. 2014 Apr;43(4):1216. Dosage error in article text. Erratum in: Eur Respir J. 2018 Jul 27;52(1):. Eur Respir J. 2022 Jun 9;59(6):.
•   Farne HA, Wilson A, Powell C, Bax L, Milan SJ
  Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017 Sep 21;9:CD010834. doi: 10.1002/14651858.CD010834.pub3. Review. Update in: Cochrane Database Syst Rev. 2022 Jul 12;7:CD010834.
•   Maio S, Baldacci S, Bresciani M, Simoni M, Latorre M, Murgia N, Spinozzi F, Braschi M, Antonicelli L, Brunetto B, Iacovacci P, Roazzi P, Pini C, Pata M, La Grasta L, Paggiaro P, Viegi G; AGAVE group
  RItA: The Italian severe/uncontrolled asthma registry. Allergy. 2018 Mar;73(3):683-695. doi: 10.1111/all.13342. Epub 2017 Nov 22.
•   McDonald VM, Hiles SA, Godbout K, Harvey ES, Marks GB, Hew M, Peters M, Bardin PG, Reynolds PN, Upham JW, Baraket M, Bhikoo Z, Bowden J, Brockway B, Chung LP, Cochrane B, Foxley G, Garrett J, Jayaram L, Jenkins C, Katelaris C, Katsoulotos G, Koh MS, Kritikos V, Lambert M, Langton D, Lara Rivero A, Middleton PG, Nanguzgambo A, Radhakrishna N, Reddel H, Rimmer J, Southcott AM, Sutherland M, Thien F, Wark PAB, Yang IA, Yap E, Gibson PG
  Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology. 2019 Jan;24(1):37-47. doi: 10.1111/resp.13389. Epub 2018 Sep 19.
•   Novelli F, Latorre M, Vergura L, Caiaffa MF, Camiciottoli G, Guarnieri G, Matucci A, Macchia L, Vianello A, Vultaggio A, Celi A, Cazzola M, Paggiaro P; Xolair Italian Study Group
  Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther. 2015 Apr;31:123-9. doi: 10.1016/j.pupt.2014.09.007. Epub 2014 Sep 30.
•   Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, Cullinan P, Custovic A, Ducharme FM, Fahy JV, Frey U, Gibson P, Heaney LG, Holt PG, Humbert M, Lloyd CM, Marks G, Martinez FD, Sly PD, von Mutius E, Wenzel S, Zar HJ, Bush A
  After asthma: redefining airways diseases. Lancet. 2018 Jan 27;391(10118):350-400. doi: 10.1016/S0140-6736(17)30879-6. Epub 2017 Sep 11. Review.
•   Peters SP, Ferguson G, Deniz Y, Reisner C
  Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med. 2006 Jul;100(7):1139-51. Epub 2006 May 18. Review.
•   Varsano S, Segev D, Shitrit D
  Severe and non-severe asthma in the community: A large electronic database analysis. Respir Med. 2017 Feb;123:131-139. doi: 10.1016/j.rmed.2016.12.017. Epub 2016 Dec 28.

RIsk Factors, Diagnosis, and Management of SEvere/Uncontrolled Asthma From General Population to Clinical Setting: Update and Follow-up of the RItA Registry

Details for clinical trial NCT05114447